


FORM PTO-1390 (REV02-2005)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET #: 33900-184PUS
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371				107552309 <small>U.S. APPLICATION NO. (Unknown see 37 CFR 1.5)</small>
INTERNATIONAL APPLICATION NO. PCT/FR2004/000870	INTERNATIONAL FILING DATE 8 April 2004		PRIORITY DATE CLAIMED 10 April 2003	
TITLE OF INVENTION Crosslinking of Low-Molecular Weight and High-Molecular Weight Polysaccharides; Preparation of Injectable Monophase Hydrogels; Polysaccharides and Hydrogels Obtained				
APPLICANT(S) FOR DO/EO/US Pierre LEBRETON				
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 				
Items 11. to 20. Below concern other document(s) or information included:				
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825 18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: (<i>specify</i>): Int'l Preliminary Examination Report, Int'l Search Report and PCT Request 				

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/552309	INTERNATIONAL APPLICATION NO. PCT/FR2004/000870	ATTORNEY'S DOCKET NUMBER 33900-184PUS
The following fees are submitted:		
21. [x] Basic National Fee (37 CFR 1.492(a)(1)-(5)) \$300 \$ 300		
<input checked="" type="checkbox"/> Examination Fee If International preliminary examination report is prepared by USPTO and all claims satisfy the provisions of PCT article 33(1)-(4) \$0 \$ 200 All other situations \$200		
22. [x] Search Fee If International preliminary examination report is prepared by USPTO and all claims satisfy the provisions of PCT article 33(1)-(4) \$0 \$ 400 Search fee (37 CFR 1.445(a)(2)) has been paid on the International application to the USPTO as an International Searching Authority \$100 International Search Report prepared and provided to the Office or previously provided to the office \$400 All other situations \$500		
ENTER APPROPRIATE BASIC FEE AMOUNT (total of 21, 22 and 23) = \$ 900		
[] Application Fee for specification and drawing filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.		
Total Sheets	Extra Sheets	Number of additional 50 or fraction thereof (round up to a whole number)
-100 =	/50 =	x \$250 \$
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).		
Claims	Number Filed	Number Extra
Total Claims	16 - 20 =	0 x \$ 50.00 \$
Independent Claims	1 - 3 =	0 x \$200.00 \$
Multiple dependent claim(s) (if applicable) + \$360.00 \$		
TOTAL OF ABOVE CALCULATIONS = \$ 900		
[] Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.		
SUBTOTAL = \$ 900		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)). + \$		
TOTAL NATIONAL FEE = \$ 900		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 40		
TOTAL FEES ENCLOSED \$940		
Amount to be refunded: \$		
Amount to be charged: \$		
a. [x] A check in the amount of \$ 940 to cover the above fees is enclosed. b. [] Please charge my Deposit Account No. <u>03-2412</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. [x] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>03-2412</u> . A duplicate copy of this sheet is enclosed.		
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
SEND ALL CORRESPONDENCE TO: <u>Martin B. Pavane</u> <u>Cohen, Pontani, Lieberman & Pavane</u> <u>551 Fifth Avenue, Suite 1210</u> <u>New York, New York 10176</u>		 <u>Edward M. Weisz</u> <u>Registration Number: 37,251</u> October 7, 2005 <u>Tel: (212) 687-2770</u>

TO did not receive the following
listed item(s) ND Assignment Document

Attorney Docket # 33900-184PUS

By Express Mail #EV129275698US

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re National Phase PCT Application of
Pierre LEBRETON

Int'l PCT Appln. No.: PCT/FR2004/000870

Int'l Filing Date: 8 April 2004

For: Crosslinking of Low-Molecular
Weight and High-Molecular
Weight Polysaccharides;
Preparation of Injectable
Monophase Hydrogels;
Polysaccharides and Hydrogels
Obtained

Check box if applicable:

DUPLICATE

**GENERAL AUTHORIZATION FOR PAYMENT OF FEES
AND PETITIONS FOR EXTENSIONS OF TIME**
Submit an original and a duplicate for fee processing

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 03-2412

- [X] Any filing fees required under 37 CFR §1.16.
- [X] Any patent application processing fees under 37 CFR §1.17 not otherwise paid by check.
- [X] The issue fee set in 37 CFR 1.18 at 3 months from mailing of the Notice of Allowance, pursuant to 37 CFR 1.311 (b) provided the fee has not already been paid by check.
- [X] Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By


Edward M. Weisz

Reg. No. 37,257

551 Fifth Avenue, Suite 1210
New York, New York 10176
(212) 687-2770

Dated: October 7, 2005

10/552309
By Express Mail

JC20 Rec'd PCT/PTO 07 OCT 2005

APPLICANT: Pierre LEBRETON

TITLE: CROSSLINKING OF LOW-MOLECULAR WEIGHT AND HIGH-MOLECULAR WEIGHT POLYSACCHARIDES; PREPARATION OF INJECTABLE MONOPHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED.

U.S. COMPLETION OF

INTERNATIONAL APPLICATION PCT/FR2004/000870 FILED APRIL 8, 2004

VERIFICATION OF A TRANSLATION

I, (name and address of translator) Marie-Claude NIEPS of 158, rue de l'Université, 75007 PARIS - FRANCE hereby declare that:

My name and post office address are as stated above:

That I am knowledgeable in the English Language and the French Language and that I believe the English translation of the specification, claims, and abstract relating to International Application PCT/FR2004/000870 filed APRIL 8, 2004 is a true and complete translation.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


(signature of translator)

Date SEPTEMBER 20, 2005